CORBUS PHARMACEUTICALS™

Advancing the Development of Novel Therapies for Rare Inflammatory and Fibrotic Diseases

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.

Clinical Pipeline: Multiple Opportunities in Rare Autoimmune / Inflammatory / Fibrotic Diseases

	Indication	Patient Population	Phase of Development	Orphan Designation	Fast Track Status	Open-Label Extension	Nondilutive Funding	Status
Autoimmune	Systemic Sclerosis (SSc)	~90,000 (US+EU)	Phase 3 RESOLVE-1 underway	✓	✓	✓		• Dosing • Potential commercial launch in 2021
Autoimmune	Dermatomyositis (DM)	~80,000 (US+EU+JPN)	Phase 2a completed	✓		✓	✓ NIH Funded[1]	Phase 3 study expected to commence end of 2018
Autoimmune	Systemic Lupus Erythematosus (SLE)	~500,000 (US+EU)	Phase 2a underway				✓ NIH Funded[1]	Dosing
Genetic / Inflammatory	Cystic Fibrosis (CF)	~75,000 (worldwide)	Phase 2b underway	✓	✓		$30MM Awarded from CFF[2]	Dosing

1: NIH grants fund Phase 2 trials of lenabasum in dermatomyositis and systemic lupus erythematosus; Corbus retains all rights to the product and owns the IND data; 2: $5 million awarded in 2015 for first Phase 2 study, project completed; up to additional $25 million development awarded in 2018 towards Phase 2b study

700,000

people living with these 4 conditions in the 7 Major Markets

Expected Milestones

2018

SSc:
- ✓ Dose first patient in Phase 3 RESOLVE-1 study
- ✓ Report data from OLE

CF:
- ✓ Commence Phase 2b study
- ✓ Dose first patient in Phase 2b study

DM:
- ✓ Report data from OLE
- ✓ Orphan Drug Designation
- Launch Phase 3 study

SLE:
- ✓ Dose first patient in Phase 2 study

2019

SSc:
- Complete dosing in Phase 3 RESOLVE-1 study

CF:
- Complete enrollment and patient dosing in Phase 2b study

DM:
- Complete enrollment in Phase 3 study

SLE:
- Complete dosing in Phase 2 study

2020

SSc:
- Report data from Phase 3 RESOLVE-1 study
- Prepare NDA filing

CF:
- Report topline results from Phase 2b study

DM:
- Report topline results from Phase 3 study

SLE:
- Report topline results from Phase 2 study

2021

SSc:
- Commercial launch

NASDAQ:	**CRBP**
Share Price*:	**$5.45**
Market Cap*:	**$311M**
Shares Outstanding:	**57.1M**

Average daily trading volume 406K shares
*As of September 4, 2018

Management Team

Yuval Cohen, Ph.D.
Chief Executive Officer, Director

Mark Tepper, Ph.D.
President, Chief Scientific Officer

Barbara White, M.D.
Chief Medical Officer

Sean Moran, M.B.A., C.P.A.
Chief Financial Officer

Robert Discordia, Ph.D.
VP, Pharmaceutical Development & Manufacturing

Ross Lobell
VP, Regulatory Affairs

Board of Directors

Amb. Alan Holmer - *Chairman*
Former Chief Executive Officer of PhRMA and Chair of Cystic Fibrosis Foundation Chapter, Washington, DC

Avery W. Catlin - *Director*
Retired Chief Financial Officer, Celldex

David Hochman - *Director*
Managing Partner, Orchestra Medical Ventures

John K. Jenkins, MD - *Director*
Distinguished 25-year career serving at the U.S. Food and Drug Administration

Paris Panayiotopoulos - *Director*
Former President and Chief Executive Officer and a member of the Board of Directors of ARIAD Pharmaceuticals, Inc

Institutional Investor Inquiries:
Corbus Pharmaceuticals, Inc.
Ted Jenkins, Senior Director,
Investor Relations and Communications
Phone: 617.415.7745
Email: ir@corbuspharma.com

All Other Investor Inquiries:
Jenene Thomas Communications
Jenene Thomas
Phone: 833.475.8247
Email: crbp@jtcir.com

CORBUS PHARMACEUTICALS™

Advancing the Development of Novel Therapies for Rare Inflammatory and Fibrotic Diseases

Systemic Sclerosis Ongoing Phase 3 RESOLVE-1 Study

Topline Data Expected 2020

Dosing: 20mg BID or 5mg BID or placebo

Double-blind
randomized, placebo-controlled
52 week study

~354 Subjects
1:1:1 *overall ratio of lenabasum:placebo*

Multinational

Primary Endpoint:
Change from baseline in mRSS

Secondary Endpoints:
Change from baseline in HAQ-DI; ACR CRISS; Change from baseline in FVC % predicted

Dermatomyositis Upcoming Phase 3 Clinical Study

Study to Commence Q4 2018

Dosing: 20mg BID or 5mg BID or placebo

Double-blind
randomized, placebo-controlled
52 week study

~150 Subjects
2:1:2 *overall ratio of lenabasum:placebo*

International

Primary Endpoint:
ACR/ACR/EULAR 2016 Total Improvement Score (TIS) in Adult Dermatomyositis & Polymyositis

Secondary Endpoints:
Change in the Cutaneous Dermatomyositis Activity and Severity index "CDASI"

Cystic Fibrosis Ongoing Phase 2b Study

Topline Data Expected 2020

Dosing: 20mg BID or 5mg BID or placebo

Double-blind
randomized, placebo-controlled
28 week study

~415 Subjects
2:1:2 *overall ratio of lenabasum:placebo*

~100 clinical sites across North America, Europe, Israel and Australia

Primary Endpoint:
Event rate of pulmonary exacerbations 20mg BID vs. placebo
- Physician decision to treat with oral, intravenous or inhaled antibiotic(s) in the presence of at least 4/12 Fuch's criteria

Secondary Endpoints:
Other measures of pulmonary exacerbations; CFQ-R Respiratory Domain Score; FEV1 % predicted

Target Indication Overview

Systemic Sclerosis

Chronic inflammatory autoimmune disease causing fibrosis of skin and internal organs

90,000 Patients in the US & EU

No SSc-Specific medicines currently approved by the FDA

80% Female Patients

40%-60% Mortality in 10 years

Dermatomyositis

Serious systemic autoimmune condition characterized by distinct skin lesions that can be accompanied by erosions, photosensitivity, itch, ulcers, calcinosis and hair loss as well as muscle inflammation and wasting

80,000 Patients in the US, EU & JPN

80% Female Patients

Currently treated with immunosuppressive therapies, but with significant toxicities

5 Year mortality rate as high as 25%

Cystic Fibrosis

Genetic disease primarily affecting the lungs and digestive system. CF involves chronic inflammation that leads to lung damage and fibrosis, which affects life quality & life span

75,000 Patients in the US & EU

No Drug currently approved by the FDA targeting inflammation and fibrosis

PEx
Pulmonary Exacerbations (PEx) main driver of morbidity and mortality

Systemic Lupus Erythematosus

Chronic autoimmune disease in which the immune system attacks the body, leading to widespread inflammation and tissue damage

500,000 Patients in the US & EU

Only One Drug currently approved for use by the FDA

Occurs More Often in Women of Child Bearing Age